

1 **PREDICTORS FOR PARTICIPATION IN MASS-TREATMENT AND FEMALE GENITAL**
2 **SCHISTOSOMIASIS RE-INVESTIGATION, AND THE EFFECT OF PRAZIQUANTEL TREATMENT IN**
3 **SOUTH AFRICAN ADOLESCENTS**

4 **Takalani Girly Nemungadi^{1*}, Elisabeth Klepp², Hashini Nilushika Galappaththi-Arachchige², Pavitra**
5 **Pillay³, Svein Gunnar Gundersen⁴, Birgitte Jyding Vennervald⁵, Patricia D. Ndhlovu⁶, Myra Taylor¹,**
6 **Saloshni Naidoo¹, Eyrun F. Kjetland^{1,2}**

7

8 ¹Discipline of Public Health Medicine, College of Health Sciences, University of KwaZulu-Natal,
9 Durban, South Africa

10 ² Norwegian Centre for Imported and Tropical Diseases, Oslo University Hospital, Oslo, Norway

11 ³Department of Biomedical and Clinical Technology, Durban University of Technology, KwaZulu-
12 Natal, South Africa

13 ⁴Institute for Global Development and Planning, University of Agder, Kristiansand, Norway

14 ⁵Section for Parasitology and Aquatic Pathobiology, Faculty of Health and Medical Sciences,
15 University of Copenhagen, Copenhagen, Denmark

16 ⁶BRIGHT Academy, Ugu District, South Africa

17

18 *Corresponding author: Takalani Girly Nemungadi, University of KwaZulu-Natal, School of Nursing
19 and Public Health, Durban, South Africa, 4041 (Email: takalaninemungadi@gmail.com)

20

Keywords. Female genital schistosomiasis; FGS symptoms; homogenous yellow patch; grainy
sandy patch, mass drug administration, treatment.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21

Type of Article: Clinical Article

22

ABSTRACT

23 Objective

24 Female Genital Schistosomiasis (FGS) causes intravaginal lesions and symptoms that could be
25 mistaken for sexually transmitted diseases or cancer. In adults, FGS lesions are refractory to
26 treatment. The effect of treatment has never been explored in young women; it is unclear if
27 gynaecological investigation will be possible in this young age group (16 – 23 years). We
28 explored the predictors for accepting anti-schistosomal treatment and/or gynaecological
29 reinvestigation in young women, and the effects of anti-schistosomal mass-treatment
30 (praziquantel) on the clinical manifestations of FGS at an adolescent age.

31

32 Method

33 The study was conducted in randomly selected, rural, high schools in Ilembe, uThungulu and
34 Ugu Districts, KwaZulu-Natal Province, East Coast of South Africa. At baseline, after obtaining
35 ethical approval and informed consent, gynaecological investigations were conducted in
36 female learners in grades 8 to 12 (aged 16-23 years). Mass-treatment was offered in the low-
37 transmission season between May and August (a few in September), in accordance with WHO
38 recommendations. Reinvestigation was offered after a median of 9 months (range 5-14
39 months). Univariate, multivariable and logistic regression analysis were used to measure the
40 association between variables.

41

42 Results

43 Of the 2293 learners who came for baseline gynaecological investigations, 1045 (46%) had
44 signs of schistosomiasis, 209/1045 (20%) had grainy sandy patches; 208/1045 (20%)
45 homogenous yellow patches; 772/1045 (74%) had abnormal blood vessels; and 404/1045
46 (39%) were urine positive. Overall, only 26% (587/2293) learners participated in the mass
47 treatment and 17% (401/2293) participated in the follow up gynaecological reinvestigations.
48 More than 70% of learners with FGS lesions were lost to follow-up: 156/209 (75%) grainy
49 sandy patches; 154/208 (74%) homogenous yellow patches; 539/722 (75%) abnormal blood
50 vessels; 238/404 (23%) urine positive. The grade 12 pupil had left school and did not
51 participate in the reinvestigations. Amongst those with lesions who came for both treatment
52 and reinvestigation, 12 (of 19) still had grainy sandy patches, 8 (of 28) had homogenous yellow
53 patches, and 54 (of 90) had abnormal blood vessels. Only 3 out of 55 remained positive for *S.*
54 *haematobium* ova. The low mass treatment uptake and huge loss to follow up among those
55 who had baseline FGS contributed to small sample size at follow up, to understand the effect
56 of treatment. However, multivariable analysis showed that treatment had effect on the
57 abnormal blood vessels (adjusted odds ratio = 2.1, 95% CI 1.1 – 3.9 and p 0.018). HIV, current
58 water contact, water contact as a toddler and urinary schistosomiasis influenced participation
59 in mass treatment. Grainy sandy patches, abnormal blood vessels, homogenous yellow
60 patches, previous pregnancy, current water contact, water contact as a toddler and father
61 present in the family were strongly associated with coming back for follow-up gynaecological
62 investigation.

63

64 Conclusion

65 Compliance to treatment and gynaecological reinvestigation was very low. There is need to
66 embark on large scale awareness and advocacy in schools and communities before
67 implementing mass-treatment and investigation studies. Further investigations with large

68 sample size are needed in order to fully understand the effect of treatment on FGS lesions,
69 including the right timing for treatment.

70

71 AUTHOR SUMMARY

72 Female genital schistosomiasis (FGS) is a neglected tropical disease and it affects many
73 women and young girls in schistosomiasis endemic areas. A lot of research is still needed to
74 understand the characteristics of FGS, its prevention, as well as the timing for treatment. As
75 a result of the limited information, some women who suffer from FGS end up being diagnosed
76 as suffering from diseases such as human papilloma virus or other sexually transmitted
77 diseases. The study highlights issues that need to be taken into considerations when providing
78 treatment or conducting mass treatment for schistosomiasis and FGS or planning
79 gynaecological investigations to inform FGS control programmes. In this study of adolescent
80 girls and young women of KwaZulu-Natal Province of South Africa, we sought to explore the
81 factors that influence participation in mass treatment and gynaecological investigation, and
82 investigating the effect of praziquantel treatment on FGS. Factors that influenced
83 participation in mass treatment included HIV, current water contact, water contact as a
84 toddler and urinary schistosomiasis. Factors that influenced participation in follow up
85 gynaecological investigation included grainy sandy patches, abnormal blood vessels,
86 homogenous yellow patches, previous pregnancy, current water contact, water contact as a
87 toddler and father present in the family. There was low uptake and huge loss to follow up for
88 mass treatment, and this contributed to small sample size for follow up gynaecological
89 investigations to understand the effect of treatment. However, multivariable analysis
90 showed that treatment had effect on the abnormal blood vessels and not on grainy sandy
91 patches and homogenous yellow patches.

92

93

94

95 INTRODUCTION

96 Female Genital Schistosomiasis (FGS) is a complication of schistosomiasis that results from
97 trapped schistosome eggs, which damage tissues and organs (1,2). It is known to affect
98 females of all age groups. FGS has a complex disease manifestation spectrum, including
99 lesions of the cervix and vagina (grainy sandy patches and homogenous yellow patches),
100 surface bleeding, abnormal blood vessels and rubbery papules (3,4). FGS has also been
101 associated with sub-fertility or infertility, ectopic pregnancy, spontaneous abortion,
102 premature birth, and increased susceptibility to HIV transmission and possibly progression.
103 Reports suggest that eggs are evenly distributed in the genital organs (2,5–7). There are many
104 case reports of concurrent FGS with cervical intra-epithelial neoplasia and one paper to date
105 has shown lower Human Papillomavirus (HPV) clearance in FGS positive women or increased
106 susceptibility to HPV (3,8–12).

107

108 WHO recommends mass drug administration in schistosomiasis endemic schools for
109 prevention of morbidity, and studies indicate that early treatment may be necessary to
110 prevent genital lesions in adulthood (13–15). **In South Africa, there is no mass treatment or**
111 **mass drug administration programme** for schistosomiasis and treatment is case-by-case
112 upon consultation by the affected individuals. The mass treatment that was conducted
113 between 1998 and 2001 in KwaZulu-Natal was discontinued due to resource constraints
114 (16,17). FGS is not known among most health care workers, clinicians and community
115 members and only approximately 160 gynaecologists were previously informed about FGS in
116 South Africa (16–19). As a result, FGS is not considered a priority condition. There is therefore
117 limited data and research and this leads to a low index of suspicion by clinicians and FGS
118 lesions often being misclassified as sexually transmitted infections or cervical cancer (2,5,20–
119 27). There have been efforts by authorities in South Africa to mobilise WHO-donated

120 praziquantel in order to implement the mass treatment as per the recommended WHO
121 strategy over the past years. However, this has been a challenge since, the donated
122 praziquantel is not registered in the country and is not permitted to be used (28).
123 Subsequently, treatment has been mobilised from within the country and mass treatment is
124 being planned for implementation (29). In order to prevent low uptake and to properly plan
125 for the roll-out of the mass treatment, it is important to identify factors that will influence
126 participation, and to determine the effect of treatment on FGS symptoms. **It is also important**
127 **to identify factors that will influence participation in gynaecological investigation in order**
128 **to improve treatment and other prevention and control measures as well as research**
129 **information that will provide new knowledge.**

130

131 Between 2011 and 2013, we conducted a follow-up study and sought to explore the feasibility
132 of the implementation of mass drug administration and gynaecological investigations in
133 school-going young women in rural KwaZulu-Natal, and to explore the effects on lesions and
134 symptoms.

135 MATERIALS AND METHODS

136 **Ethical considerations.** The study was approved by the Biomedical Research Ethics
137 Committee (BREC), University of KwaZulu-Natal (Ref BF029/07), KwaZulu-Natal Department
138 of Health (Reference HRKM010-08) and the Regional Committee for Medical and Health
139 Research Ethics (REC), South Eastern Norway. The ethical committees were aware that minors
140 were invited into the study and specifically approved independent minor consent without
141 parental consent. All study participants were offered anti-schistosomal treatment and, if
142 applicable, treatment for sexually transmitted diseases, and/or referral to the local health
143 system for treatment of HIV.

144

145 **Study subjects and area.** The study was conducted between 2011 and 2015 in the KwaZulu-
146 Natal Province of South Africa. The participants were female learners aged 16 – 23 years, from
147 randomly selected high schools in Ilembe, uThungulu and Ugu Districts on the East Coast of
148 South Africa that had not undergone anti-schistosomal mass-treatment before the first
149 investigation as shown in Table 1. The participants were recruited from schools that were
150 classified as rural by the South African Department of Basic Education and were below the
151 altitude of 400 meters above sea level, with an estimated prevalence of *S. haematobium* of
152 10% or more based on an initial show of hands for red urine in Ugu District and a haematuria
153 dipstick survey in Ilembe and uThungulu districts (30). Gynaecological examinations were
154 performed in two research clinics (North of Durban and South of Durban); virgins, pregnant,
155 and severely ill females were excluded. Schools with prevalence of less than 10% were
156 excluded

157 **Table 1.** Study design and practicalities, their rationale, and the potential unintended
 158 consequences

| Inclusion considerations | Reason |
|---|--|
| Participants included were 16 years and above, including Grade 12 | In order to explore reversibility of lesions, we wished to invite young women at an earliest possible time for a gynaecological investigation. However, gynaecological investigations are not practically feasible before the age of 16 for cultural, legal and sometimes anatomical reasons (31). Average sexual debut age is 18.7 years in South Africa and many hide sexual debut from e.g. their parents and teachers for as long as they can (32,33). Moreover, some may be worried about the "loss of virginity" during speculum examination (34,35). Visual inspection of the cervix, fornices and vaginal surfaces before sexual debut may therefore be offensive to their sensibilities. |
| KwaZulu-Natal was chosen as the study area | Firstly, at this tender age, chances were high that these young women would be invited for their first gynaecological examination. Some amongst the pupils might be found to have been raped and a gynaecological examination might trigger psychological reactions. Therefore, we looked for a study area where psychologists and support centres would be available for study participants in a schistosomiasis endemic area. Secondly, there are more than 4,000 rural schools in KZN and we estimated that we would be able to reach the necessary sample size (36,37). |
| Although some young women with multiple lesions were treated at the clinic, most were not done immediately after examination at the clinic. | Treatment with praziquantel was done at schools, not at the research clinics for the following reasons: 1) Mass Drug Administration is recommended so that siblings and class mates are treated simultaneously (15) 2) Anti-schistosomal treatment with Praziquantel should be given in the low-transmission season (28,38) 3) Praziquantel may cause nausea and sometimes vomiting; if treatment had been done at clinic immediately after investigation, some learners might become car sick on the way from the clinic, it could potentially scare others from participating (15). |

159
 160

161 **Questionnaires and clinical examinations.** Group information, individual information and the
 162 consent form procedure was done at the school over a 2-week-period. Consent forms and
 163 parent information were distributed in advance (39–41). The investigation has been described
 164 previously. Briefly, a questionnaire on water contact, reproductive history, genital and
 165 abdominal symptoms was administered individually to participants in isiZulu (the local
 166 language) prior to gynaecological examination (30). Teachers would suggest days when it
 167 would be suitable to fetch learners from schools to go to the research clinic. Teenagers had
 168 indicated they were embarrassed to give urine in school so urine was collected only while

169 they were at the clinic. On pre-reserved days, a female driver, trained and well-informed
170 about the study, would pick up 4-13 participants (depending on the vehicle size) for the drive
171 to the clinic for gynaecological examinations.

172

173 **Treatment.** In accordance with the WHO policy for areas of high schistosomiasis endemicity,
174 mass treatment of participants and other learners in enrolled schools was carried out during
175 the winter season (low-transmission season) after the baseline gynaecological examination.
176 Treatment began after lunch to ensure that the children had eaten their free school lunches
177 before treatment and to save the costs on food for the programme. Depending on the size of
178 school, the treatment team comprised of 2-4 nurses and 2-4 assistants (27). Bread and
179 bananas were distributed to learners who had not received a school lunch. Learners with
180 signed consent forms were weighed, and the number of praziquantel tablets was calculated
181 for the dose of 40 mg per kg of body weight. As described previously, a designated nurse
182 directly observed all tablet ingestion by counting the number of tablets in each learner's hand
183 and watching for hand-to-mouth intake (27). The treatment team stayed in the school for an
184 hour after the last dose to allow learners to report any side effects. All learners, even the
185 untreated, were allowed to come back for follow-up gynaecological examination.

186

187 **Sample size calculation and statistical analyses.** Demographic and clinical variables were
188 explored as predictors for (1) participation in mass-treatment and (2) returning to a follow-
189 up gynaecological investigation. We planned a study of independent cases and controls with
190 3 control(s) per case. Prior data indicated that the probability of coming back for a
191 gynaecological investigation among those with FGS disease is 15%. If the true probability of
192 FGS among those who do not return is 9%, we will need to study 318 FGS patients and 954
193 without FGS to be able to reject the null hypothesis that the exposure rates for the groups

194 are equal with probability (power) 80%. The Type I error probability associated with this test
195 of this null hypothesis is 0.05. We will use an uncorrected chi-squared statistic to evaluate
196 this null hypothesis.

197

198 In order to study simultaneously the impact of several variables, logistic regression analysis
199 was applied with a 5% significance level; as a general rule variables were included if the p-
200 value from the crude association was less than 0.2 and if the Spearman rank correlation
201 coefficient was below 0.7. Age was forced into the model.

202

203 To assess the overlap of the FGS lesions among the learners, we created Venn diagrams using
204 Venny version 2.1 (Juan Carlos Oliveros,
205 <https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html>)


206

207 RESULTS

208 **Description of the study population.**

209 A total of 2293 adolescent girls and young women from 70 secondary schools were enrolled and
210 examined gynaecologically for FGS lesions at baseline. As shown in Figure 1, 1045/2293 (46%) learners
211 had genital lesions or signs of urinary schistosomiasis at baseline. None of them had rubbery papules.
212 Abnormal blood vessels were the most common findings.

213




214

215 Figure 1. Genital lesions and signs for schistosomiasis amongst adolescent girls and young
216 women in Kwa-Zulu-Natal between 2012 and 2013.

217

218 As shown in Figure 2, 271 learners had more than one FGS lesions while 556 had only one FGS
219 lesion (ABV: abnormal blood vessels, GSP: grainy sandy patches, HYP: homogenous yellow
220 patches).

221



222

223 Figure 2. Venn diagram showing an overlap of baseline FGS lesions among learners.

224

225 **Mass treatment participation**

226 Treatment with praziquantel (40mg/kg) was given in the low-transmission season (South
227 African winter between May and August, including a few in September). Only 26% (587 of the
228 2293) learners were treated between baseline and follow-up. Multivariable analysis showed
229 that HIV, current water contact, water contact as a toddler and urinary schistosomiasis
230 positively influenced learners' willingness to participate in the mass treatment (Table 2). A
231 greater loss to follow-up for mass treatment was observed in the Southern research clinic as
232 compared to the Northern clinic (odds ratio = 2.1, 95% CI 1.7 – 2.6 and $p < 0.001$).

233

234

235

Table 2. Underlying factors and compliance with mass-treatment

| History | Participated in mass treatment (%) | Did not participate in mass treatment (%) | Univariate analysis | | | Multivariable analysis | | |
|------------------------------|------------------------------------|---|---------------------|-------------------------|---------|------------------------|-------------------------|--------------------|
| | | | Odds ratio | 95% Confidence Interval | p-value | Adjusted odds ratio | 95% Confidence Interval | p-value |
| Grade 8 | 4/209 (2) | 6/1026 (1) | 1 | | | 1 | | |
| Grade 9 | 13/209 (6) | 43/1026 (4) | 0.9 | 0.3-2.6 | 0.913 | 0.7 | 0.2-2.3 | 0.600 |
| Grade 10 | 51/209 (24) | 277/1026 (27) | 0.6 | 0.2-1.5 | 0.274 | 0.4 | 0.2-1.2 | 0.113 |
| Grade 11 | 128/209 (61) | 507/1026 (49) | 0.6 | 0.3-1.7 | 0.389 | 0.5 | 0.2-1.5 | 0.249 |
| Grade 12 | 13/209 (6) | 193/1026 (189) | 0.9 | 0.3-2.3 | 0.813 | 0.6 | 0.2-0.7 | 0.346 |
| Current water contact | 391/587 (59) | 596/1050 (57) | 1.5 | 1.2 – 1.9 | <0.001 | 1.4 | 0.1-1.8 | 0.003 |
| Urinary schistosomiasis | 90/517 (17) | 193/895 (22) | 0.8 | 0.6 – 1.0 | 0.060 | 0.7 | 0.5-0.9 | 0.037 |
| Abnormal blood vessels | 215/587 (37) | 337/1050 (32) | 1.2 | 0.9 – 1.5 | 0.063 | 1.1 | 0.8-1.3 | 0.680 ^a |
| | | | | | | 1.1 | 0.9-1.4 | 0.245 ^b |
| Water contact as toddler | 339/587 (58) | 611/1050 (58) | 1.5 | 1.2 – 1.9 | <0.001 | 1.4 | 1.1-1.8 | 0.002 |
| HIV | 86/555 (15) | 210/999 (21) | 0.7 | 0.5 – 0.9 | 0.008 | 0.7 | 0.5-0.9 | 0.015 |
| Red urine previously or now | 155/587 (26) | 320/1045 (31) | 0.8 | 0.6 – 1.0 | 0.072 | 0.8 | 0.7-1.1 | 0.138 |
| Mother present in the family | 375/587 (64) | 625/1045 (60) | 1.2 | 0.9 – 1.5 | 0.105 | 1.3 | 0.9-1.6 | 0.055 |
| Homogenous yellow patch | 60/587 (10) | 90/1050 (9) | 1.2 | 0.9 – 1.7 | 0.267 | | | |
| Has ever been pregnant | 280/587 (48) | 504/1050 (48) | 0.9 | 0.8 – 1.2 | 0.907 | | | |
| Heavy bleeding with clots | 176/408 (43) | 350/755 (46) | 0.9 | 0.7 – 1.1 | 0.292 | | | |
| Father present in the family | 136/587 (23) | 251/1045 (24) | 0.9 | 0.8 – 1.2 | 0.698 | | | |
| Genital itch | 361/587 (61) | 658/1046 (63) | 0.9 | 0.8 – 1.2 | 0.573 | | | |
| Genital burn | 243/587 (41) | 464/1046 (44) | 0.9 | 0.7 – 1.1 | 0.246 | | | |
| Genital sore/ulcer | 114/585 (19) | 206/1043 (20) | 0.9 | 0.8 – 1.3 | 0.898 | | | |
| Genital lump | 93/583 (16) | 176/1038 (17) | 0.9 | 0.7 – 1.2 | 0.602 | | | |
| Urge with leak | 270/587 (46) | 499/1045 (48) | 0.9 | 0.8 – 1.1 | 0.496 | | | |
| Urge | 202/585 (35) | 346/1044 (33) | 1.1 | 0.9 – 1.3 | 0.569 | | | |
| Dysuria | 297/587 (35) | 550/1044 (52) | 0.9 | 0.8 – 1.1 | 0.418 | | | |
| Bloody discharge | 104/583 (17) | 198/1043 (19) | 0.9 | 0.7 – 1.2 | 0.569 | | | |
| Watery discharge | 369/583 (63) | 638/1039 (61) | 1.1 | 0.9 – 1.3 | 0.452 | | | |
| Abnormal discharge smell | 260/583 (45) | 490/1042 (47) | 0.9 | 0.7 – 1.1 | 0.346 | | | |
| Grainy sandy patch | 49/587 (8) | 102/1050 (8) | 0.8 | 0.6 – 1.2 | 0.359 | | | |

^amultivariable with abnormal blood vessels and current water contact, ^bmultivariable with abnormal blood vessels and water contact as a toddler.

236 Gynaecological reinvestigation

237 Table 3 shows that a total of 709 learners (31% of the 2293 learners) were interviewed at
 238 follow up. Of the 709, 398 agreed to participate in the follow up gynaecological investigation;
 239 the majority (32%) felt that they were not ready. The willing participants were reinvestigated
 240 after a median of 9 months (range 5 - 14 months). The median age of those followed-up was
 241 19 years (range 16 - 23 years), and those who were lost to follow-up had a median age of 18
 242 years (range 16 – 23 years).

243

244 Table 3. Reasons for refusing follow up gynaecological examination (n=709)

| Reasons for denying or aborting gynaecological examination | Came for follow up | | Total (%) |
|--|--------------------|-----------------|------------------|
| | No (%) | Yes (%) | |
| Did not deny or abort | 16 (3.9) | 398 (%) | 414 (100) |
| Fear | 26 (100) | 0 (0) | 26 (100) |
| Not ready | 127 (100) | 0 (0) | 127 (100) |
| Menstruation | 24 (92) | 2 (8) | 26 (100) |
| Virgin | 14 (100) | 0 (0) | 14 (100) |
| Pregnant | 53 (100) | 0 (0) | 53 (100) |
| Other | 48 (98) | 1 (2) | 49 (100) |
| TOTAL | 308 (43) | 401 (57) | 709 (100) |

245

246 Table 4 show factors that may have contributed to compliance with follow up gynaecological
 247 investigation. The three FGS lesions (grainy sandy patches, abnormal blood vessels and
 248 homogenous yellow patches), previous pregnancy, current water contact, water contact as a
 249 toddler and father present in the family were strongly associated with coming back for a
 250 follow-up investigation in both univariate and multivariable analysis. Multivariable analysis of
 251 the three FGS lesions individually (to account for a causal relationship) with current water
 252 contact, previous pregnancy and water contact as a toddler had no effect on the association.
 253 A greater loss to follow-up for gynaecological investigation was observed in the Southern
 254 research clinic as compared to the Northern clinic (odds ratio = 1.9, 95% CI 1.5 – 2.4 and p
 255 <0.001).


Table 4. Underlying factors associated with coming back for follow-up gynaecological investigations

| History | Came for follow-up (%) | Did not come for gynaecological investigation | Univariate analysis | | | Multivariable analysis | | |
|--------------------------------|------------------------|---|---------------------|-------------------------|---------|------------------------|-------------------------|---------|
| | | | Odds ratio | 95% Confidence Interval | p-value | Adjusted odds ratio | 95% Confidence Interval | p-value |
| Grade 8 | 5/400 (1) | 18/1863 (1) | 1 | | | 1 | | |
| Grade 9 | 24/400 (7) | 92/1863 (5) | 0.9 | 0.3-2.8 | 0.910 | 0.8 | 0.3-2.5 | 0.724 |
| Grade 10 | 120/400 (30) | 488/1863 (26) | 0.9 | 0.3-2.4 | 0.813 | 0.8 | 0.3-2.2 | 0.635 |
| Grade 11 | 214/400 (54) | 742/1863 (40) | 1.0 | 0.4-2.8 | 0.941 | 0.9 | 0.3-2.5 | 0.803 |
| Grade 12 | 37/330(6) | 523/1863 (28) | 0.3 | 0.1-0.7 | 0.010 | 0.2 | 0.1-0.6 | 0.004 |
| Grainy sandy patch* | 56/401 (14) | 153/1892 (8) | 1.8 | 1.3-2.6 | <0.001 | 1.8 | 1.3-2.6 | <0.001 |
| Abnormal blood vessels* | 185/401 (46) | 537/1892 (28) | 2.3 | 1.7-2.7 | <0.001 | 2.2 | 1.7-2.7 | <0.001 |
| Homogenous yellow patch* | 55/401 (14) | 153/1892 (8) | 1.8 | 1.3-2.5 | <0.001 | 1.8 | 1.3-2.5 | 0.001 |
| Has ever been pregnant | 236/401 (60) | 838/1892 (44) | 1.8 | 1.4-2.2 | <0.001 | 1.8 | 1.5-2.3 | <0.001 |
| Water contact as toddler | 260/401 (65) | 1119/1892 (59) | 1.3 | 1.0-1.6 | <0.034 | 1.4 | 1.1-1.7 | 0.009 |
| Current water contact | 257/401 (64) | 1124/1892 (59) | 1.2 | 0.9 - 1.5 | 0.082 | 1.4 | 1.1-1.7 | 0.012 |
| Red urine previously or now | 110/398 (28) | 571/1883 (30) | 0.9 | 0.7 – 1.1 | 0.287 | 0.8 | 0.6-1.1 | 0.140 |
| Father present in the family | 71/398 (19) | 454/1881 (24) | 0.7 | 0.5 – 0.9 | 0.007 | 0.7 | 0.5-0.9 | 0.010 |
| Genital lump | 65/394 (17) | 311/1872 (17) | 0.9 | 0.7 – 1.3 | 0.955 | | | |
| Condom use | 130/319 (41) | 649/1604 (41) | 1.0 | 0.8 – 1.3 | 0.923 | | | |
| Heavy bleeding with clots | 113/259 (44) | 628/1403 (45) | 0.9 | 0.7 – 1.2 | 0.736 | | | |
| HIV | 83/386 (22) | 356/1794 (20) | 1.1 | 0.8 – 1.4 | 0.461 | | | |
| Mother present in the family | 231/399 (58) | 1136/1880 (60) | 0.9 | 0.7 – 1.1 | 0.349 | | | |
| Genital itch | 253/399 (63) | 1155/1884 (61) | 1.1 | 0.9 – 1.4 | 0.433 | | | |
| Genital burn | 179/399 (45) | 809/1884 (43) | 1.1 | 0.9– 1.3 | 0.482 | | | |
| Genital sore/ulcer | 77/398 (19) | 347/1879 (19) | 1.1 | 0.8 – 1.4 | 0.682 | | | |
| Urge with leak (urgenic1) | 200/398 (50) | 882/1883 (47) | 1.1 | 0.9 – 1.4 | 0.216 | | | |
| Urge but no leak (urge1) | 137/392 (35) | 639/1881 (34) | 1.0 | 0.8 – 1.3 | 0.837 | | | |
| Dysuria | 217/398 (55) | 982/1882 (52) | 1.1 | 0.9 – 1.4 | 0.395 | | | |
| Bloody discharge | 70/397 (18) | 356/1875 (19) | 0.9 | 0.7 – 1.2 | 0.530 | | | |
| Watery discharge | 252/396 (64) | 1168/1872 (62) | 1.1 | 0.8 – 1.3 | 0.642 | | | |
| Abnormal discharge smell | 179/399 (45) | 878/1869 (47) | 0.9 | 0.7 – 1.1 | 0.442 | | | |
| Urinary schistosomiasis | 82/367 (22) | 322/1579 (20) | 1.1 | 0.9 – 1.5 | 0.407 | | | |

*Were analysed separately because some participants were affected by more than one lesion and there may be causal relationship between the three FGS lesions.

256 On the baseline investigation day, participants were informed about genital lesions (grainy sandy
 257 patches, homogenous yellow patched and abnormal blood vessels) but urine microscopy results
 258 were not readily available as the laboratory investigation were still going on. However, only
 259 approximately 25% of the young women with lesions returned for follow-up examinations (Figure
 260 3, bold frame). As shown in Figure 3 (hatched frame), more than 70% of learners that had genital
 261 lesions or signs of FGS at baseline were lost to follow up for gynaecological investigation, and 23%
 262 of learners with urinary schistosomiasis were lost to follow-up.

263



264

265 Figure 3. Follow-up amongst adolescent girls and young women investigated for Female Genital
 266 Schistosomiasis in Kwa-Zulu-Natal.

267 Legend:

268 Hatched frame: lost to follow-up for gynaecological investigation.

269 Bold frame: Remaining findings at follow-up gynaecological investigation

270

271 **The effect of treatment**

272

273 Multivariable analysis of the effect of treatment on baseline FGS showed that treatment only
 274 had an effect on the abnormal blood vessels (adjusted odds ratio = 2.1, 95% CI 1.1 – 3.9 and
 275 p 0.018) (Table 5). Treatment was protective against urinary schistosomiasis; only 3 learners
 276 among the 55 that were treated remained positive for urinary schistosomiasis at follow up
 277 (adjusted odds ratio = 0.4, 95% CI 0.01 – 0.1 and p < 0.001).

278

279 Before accounting for FGS lesions at baseline (including those with and without FGS lesions
 280 at baseline), the univariate analysis showed a strong association between treatment and two
 281 FGS lesions (homogenous yellow patches and abnormal blood vessels); at multivariable
 282 analysis this association remained unchanged for the abnormal blood vessels (adjusted odds
 283 ratio = 2.3, 95% CI 1.5 – 3.6 and p <0.001) (Table 5) whereas it became insignificant for
 284 homogenous yellow patches.

285

286 Table 5. Effect of treatment - remaining FGS lesions among the treated and untreated

| FGS lesions | Treated (%) | Untreated (%) | Univariate analysis | | | Multivariable analysis | | |
|---|-------------|---------------|---------------------|------------|---------|------------------------|------------|---------|
| | | | OR | 95% CI | p-value | AOR | 95% CI | p-value |
| Effect of treatment among those with FGS a baseline | | | | | | | | |
| Grainy sandy patches | 12/19 (63) | 23/34 (68) | 0.8 | 0.3 – 2.7 | 0.741 | 0.5 | 1.1 – 2.1 | 0.369 |
| Homogenous yellow patches | 08/28 (29) | 03/26 (12) | 3.1 | 0.7 – 3.2 | 0.120 | 6.7 | 0.9 - 48 | 0.058 |
| Abnormal blood vessels | 54/90 (60) | 40/93 (43) | 1.9 | 1.1 – 3.6 | 0.022 | 2.1 | 1.1 – 3.9 | 0.018 |
| Urinary schistosomiasis | 3/55 (5) | 73/183 (53) | 0.5 | 0.02 - 0.2 | <0.001 | 0.4 | 0.01 – 0.1 | <0.001 |
| Overall FGS rate at follow up (after treatment and including FGS among those who did not have FGS at baseline) | | | | | | | | |
| Grainy sandy patches | 25/167 (15) | 35/229 (15) | 0.9 | 0.6 – 1.7 | 0.931 | 0.9 | 0.5 – 1.7 | 0.903 |
| Homogenous yellow patches | 24/167 (14) | 17/229 (07) | 2.1 | 1.1 – 4.0 | 0.025 | 1.8 | 0.9 – 3.5 | 0.096 |
| Abnormal blood vessels | 81/167 (49) | 66/229 (29) | 2.3 | 1.5 – 3.5 | <0.001 | 2.3 | 1.5 – 3.6 | <0.001 |
| Urinary schistosomiasis | 07/351 (02) | 91/681 (13) | 0.1 | 0.1 – 0.3 | <0.001 | 0.1 | 0.1 – 0.3 | <0.001 |

287

288 DISCUSSION

289 The abnormal blood vessels were refractory to praziquantel treatment. Abnormal blood
290 vessels and grainy sandy patches were previously found to be significantly associated with
291 the presence of live worms as opposed to the homogenous yellow patches (42). The
292 association between praziquantel treatment and abnormal blood vessels may be an
293 indication that abnormal blood vessels are an early stage of the grainy sandy patches and are
294 easy to eliminate as opposed to the grainy sandy patches and homogenous yellow patches. It
295 is important to note that different investigators define the investigation findings differently
296 and that the investigators of gynaecological examinations were different in baseline and
297 follow-up studies.

298

299 South Africa is not implementing mass drug administration (43); the remaining gynaecological
300 symptoms among the treated were high and may be an indication that for effectiveness,
301 several rounds of treatment are required and should be started at an earlier age. This
302 supports findings in Zimbabwe where a standard single-dose of praziquantel did not have
303 effect on the inflammatory lesions of FGS that had formed and developed over a few years
304 (13). The timing for follow up investigations may have been too soon for some learners to
305 determine the true effect of treatment (the median time period between praziquantel
306 (40mg/kg) treatment and reinvestigation was 5 months (range 5 – 14 months).

307

308 Treatment with praziquantel is the only recommended effective way of killing adult helminths
309 and mature live eggs, but has no effect on the calcified ova; early treatment is therefore
310 crucial before the ova are deposited in the tissue and cause damage (6,44). This may possibly
311 explain the remaining gynaecological symptoms among the treated, including those who did

312 not have the lesions at baseline. A retrospective study found that treatment at an early age
313 seems to prevent gynaecologic morbidity (13).

314

315 Lack of a regular mass treatment programmes in South Africa, repeated exposure to risky
316 water, and re-infections could have led to continuous FGS lesions even after a single dose of
317 praziquantel. Further investigations and follow up studies are therefore needed in countries
318 that are implementing mass drug administration and areas that are not implementing mass
319 drug administration. These studies will help with information to fully understand the
320 differences between the FGS lesions and whether praziquantel treatment can eliminate these
321 lesions, including the right timing to possibly eliminate the lesions. Currently, only one study
322 has investigated the impact of treatment on gynaecological lesions and found no significant
323 change in the adult sandy patches and contact bleeding over a 12-month period, even though
324 urinary egg excretion ceased (45). Another study found that schistosomiasis PCR remained
325 positive in the genitals after treatment (46). The lack of information and complexity in
326 conducting research on how long it takes for the FGS lesions to manifest following infection
327 made it difficult to determine whether the FGS lesions diagnosed at follow-up were due to
328 schistosomiasis re-infection or were progressive lesions that had not yet manifested and
329 therefore diagnosed at baseline. Lack of a regular mass treatment programme in South Africa,
330 repeated exposure to risky water, and re-infections could have led to continuous FGS lesions
331 even after a single dose of praziquantel.

332

333 Identification of HIV, current water contact, water contact as a toddler and urinary
334 schistosomiasis as factors that influenced learners to participate in mass treatment are in
335 consistent with the general knowledge of the impact of these factors on schistosomiasis i.e.
336 schistosomiasis as a risk factor for HIV, and water contact as a risk for schistosomiasis. The

337 pre-treatment health education may have played a role in influencing these participants to
338 accept the treatment. Learners who felt they do not have a problem with these identified
339 factors may have perceived it unnecessary for them to get treated. Furthermore, the three
340 FGS lesions (grainy sandy patches, abnormal blood vessels and homogenous yellow patches),
341 previous pregnancy, current water contact, water contact as a toddler and father present in
342 the family were strongly associated with returning for follow-up investigation. It is anticipated
343 that the investigators at the Northern clinic had gained more experience in both health
344 education and community engagement as opposed to when they conducted investigations at
345 the Southern clinic (the 1st investigation site) where there was a greater loss to follow up.
346 Therefore, active ongoing community engagement targeting both learners, parents and the
347 entire community at risk is crucial in order to empower the community with the full
348 knowledge on prevention and control that will enable them to make informed decisions.

349
350 South Africa is endemic for schistosomiasis with some focal areas having high and moderate
351 infections (42), and FGS studies among the young population may help identify targeted
352 interventions. Study findings revealed that more than 20% of the adolescent women in
353 KwaZulu-Natal province had three well-known genital mucosal manifestations of FGS (30); in
354 Limpopo Province, FGS accounted for 87.6% of the female cases in a study that described the
355 pathology of biopsy diagnosed schistosomiasis (47). However, treatment in South Africa is still
356 case-based and, as in many other countries, most community members do not seek early
357 treatment or do not seek treatment at all (17,27,48). Therefore, those infected and those that
358 complicate to FGS remain infected or with FGS complication; some individuals are
359 misdiagnosed as sexually transmitted infections (STIs) or cervical cancer (2,5,20–27). In this
360 study, loss to follow up was a major challenge. Involving community health workers in FGS
361 studies may assist with managing those who are lost to follow up because it would be easier

362 for them to maintain contact and follow up with the learners in their catchment area,
363 especially those found to have FGS symptoms.

364

365 It is important to note that gynaecological examination was not possible among the early and
366 middle adolescent group due to virginity, fear, pregnancy, and privacy and other related
367 issues. Early adolescence and some middle adolescence may only be targeted for prevention
368 and only examined at the late adolescence stage to check if they developed any FGS after
369 repeated treatment. Observational studies in young adolescents and adults are critical in
370 determining the effect of early treatment on schistosomiasis and FGS. It is similarly important
371 to determine the burden of infertility among those living in endemic areas and determine the
372 association with FGS. Therefore, it is important for countries such as South Africa to establish
373 mass drug administration programmes in order to prevent sustained infections that can lead
374 to FGS.

375

376 The high loss to follow up is worrying because more knowledge is required through research
377 to understand FGS pathogenesis and improve the knowledge of clinicians. For instance, it is
378 important to note that the high loss to follow during mass treatment in this study contributed
379 to small sample size to determine the effect of treatment on FGS. Currently, the lack of
380 knowledge of FGS among most clinicians and affected communities is concerning due to the
381 reported high prevalence of genital lesions (49). It has been reported that up to 75% of all
382 women and girls infected with urinary *S. haematobium* have lesions in the uterus, cervix,
383 vagina or vulva (4). Many women have been reported to have genital schistosomiasis without
384 urinary excretion of *S. haematobium* eggs (2,4,13,50,51). In sub-Saharan Africa, it is estimated
385 that 56 million women have FGS (2).

386

387 In addition to the identified unintended consequences due to inclusion criteria and research
388 actions reported under results, the high loss to follow-up and low treatment coverage in this
389 study could also be attributed to factors that were reported by another study in South Africa
390 in Ugu District of KwaZulu-Natal Province. This Ugu District study was conducted among grade
391 10 – 12 learners, teachers, community health workers and traditional healers (16,17). Factors
392 that contributed to low coverage in this Ugu District study were reported to be:

- 393 • older age group;
- 394 • lack of knowledge;
- 395 • attending a large school
- 396 • parental control and a closer teacher follow-up in younger children and in small
397 schools;
- 398 • misconceptions that schistosomiasis is a self-healing disease and symptoms confused
399 with sexually transmitted infections;
- 400 • the chronicity of the disease is not known to the general population;
- 401 • teasing and stigma;
- 402 • schistosomiasis-related absenteeism that may reach 30% on some days;
- 403 • tablets must be distributed by health professionals in South Africa;
- 404 • schools reluctant to provide more than one day for treatment in order to minimise
405 disturbance (15,17,27).

406 The lower loss to follow up at the North of Durban clinic may be attributed to the experience
407 gained while operation at the first clinic (South of Durban). A praziquantel mass treatment
408 programme was implemented in South Africa, in Ugu District of KwaZulu-Natal Province
409 between 1998 and 2001 among grade 10 – 12 learners, teachers, community health workers
410 and traditional healers, and only reached 44% of the learners instead of the WHO and the

411 South African National Department of Health recommended target of 75% coverage (27). This
412 shows a need to embark on large scale awareness and advocacy campaign in schools and
413 communities, coordinated by the Department of Health and in collaboration with the
414 Department of Basic Education, non-governmental organisations and community leaders,
415 before implementing FGS studies among young people and mass treatment administration,
416 to improve participation in research that will inform control measures.

417

418 Study limitations include the small sample size to determine the effect of treatment due to
419 low treatment coverage and loss to follow up. Another limitation was that treatment was not
420 done immediately after baseline, and therefore many learners were not treated between
421 baseline and follow up either due to factors described above by Lothe *et al* in the qualitative
422 studies in Ugu District, KwaZulu-Natal Province (16,17). As a result, some learners that were
423 not treated between baseline and follow up were only treated during follow-up. Some of the
424 learners under 16 years might already have had chronic lesions, and inclusion of the Grade 12
425 learners could have contributed to loss to follow up because of those who passed matric and
426 moved to tertiary institutions the following year.

427

428 In summary, it is critical to conduct vigorous ongoing community engagements for awareness
429 and buy-in prior to mass treatment and gynaecological investigations in order to improve
430 community participation. Because of the small sample size due to loss to follow-up, it is
431 difficult to draw firm conclusions about the effect of treatment on FGS lesions.

432

433

434

436 AUTHOR CONTRIBUTION

437

438 **Takalani Girly Nemungadi** conceived the presented idea, carried out the laboratory and statistical
439 analysis, contributed to the writing and finalisation of the manuscript

440 **Eyrun F. Kjetland** helped conceive the presented idea, supervised the project, carried out statistical
441 analysis, contributed to the writing and finalisation of the manuscript

442 **Saloshni Naidoo** helped supervise the project and contributed to writing

443 **Elisabeth Kleppa** contributed to conceptualisation and writing

444 **Hashini Nilushika Galappaththi-Arachchige** contributed to conceptualisation and writing

445 **Pavitra Pillay** contributed to conceptualisation and writing

446 **Svein Gunnar Gundersen** contributed to conceptualisation and writing

447 **Birgitte Jyding Vennervald** contributed to conceptualisation and writing

448 **Patricia Ndhlovu** contributed to conceptualisation and writing

449 **Myra Taylor** contributed to conceptualisation and writing

450

451 ACKNOWLEDGMENTS

452 We are appreciative of the support from Roy Manyaira, Silindile Gagai and other staff at
453 BRIGHT Research in KwaZulu-Natal, South Africa. We thank all the girls and young women
454 who participated in the study.

455

CONFLICTS OF INTEREST

456 All authors report no conflicts of interest.

457

REFERENCES

- 458 1. Hegertun IEA, Sulheim Gundersen KM, Kleppa E, Zulu SG, Gundersen SG, Taylor
459 M, et al. *S. haematobium* as a Common Cause of Genital Morbidity in Girls: A Cross-
460 sectional Study of Children in South Africa. *PLoS Negl Trop Dis*. 2013;7(3):e2104 (1-
461 8).
- 462 2. UNAIDS, World Health Organization. No more neglect. Female genital
463 schistosomiasis and HIV. Integrating reproductive health interventions to improve
464 women's lives [Internet]. Geneva, Switzerland; 2019 [cited 2020 Mar 12]. Available
465 from:
466 [https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis](https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis_and_hiv_en.pdf)
467 [_and_hiv_en.pdf](https://www.unaids.org/sites/default/files/media_asset/female_genital_schistosomiasis_and_hiv_en.pdf)
- 468 3. Kjetland EF, Norseth HM, Taylor M, Lillebø K, Kleppa E, Holmen SD, et al.
469 Classification of the lesions observed in female genital schistosomiasis. *Int J Gynaecol*
470 *Obstet* [Internet]. 2014;127:227–8. Available from:
471 [http://www.scopus.com/inward/record.url?eid=2-s2.0-](http://www.scopus.com/inward/record.url?eid=2-s2.0-84906529324&partnerID=MN8TOARS)
472 [84906529324&partnerID=MN8TOARS](http://www.scopus.com/inward/record.url?eid=2-s2.0-84906529324&partnerID=MN8TOARS)
- 473 4. Kjetland EF, Gwanzura F, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Simple
474 clinical manifestations of genital *Schistosoma haematobium* infection in rural
475 Zimbabwean women. *Am J Trop Med Hyg* [Internet]. 2005 Mar;72(3):311–9.
476 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15772328>
- 477 5. Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J. Female genital
478 schistosomiasis (FGS): from case reports to a call for concerted action against this
479 neglected gynaecological disease. *Int J Parasitol*. 2016 Jun 1;46(7):395–404.
- 480 6. World Health Organisation. Ending the neglect to attain the Sustainable Development
481 Goals: A road map for neglected tropical diseases 2021–2030. Geneva, Switzerland:
482 World Health Organisation; 2020. 1–196 p.
- 483 7. Kjetland EF, Leutscher PDC, Ndhlovu PD. A review of female genital
484 schistosomiasis. *Trends Parasitol* [Internet]. 2012;28(2):58–65. Available from:
485 <http://www.ncbi.nlm.nih.gov/pubmed/22245065>
- 486 8. Eustace D, Trehan A, Raju KS, Derias N, Pambakian H. Abdominal pain and vaginal
487 bleeding associated with schistosomiasis of the genital tract. *J Obstet Gynaecol*
488 (Lahore) [Internet]. 2009;12(6):427–8. Available from:
489 <https://doi.org/10.3109/01443619209025953>
- 490 9. Alalade AO, Leeson SC, Andrady U. An unusual association: Vulval schistosomiasis,
491 microinvasive vulval squamous cell carcinoma and high-grade vulval intraepithelial
492 neoplasia in HIV patient. *Gynecol Surg*. 2009;6(2):177–9.
- 493 10. Kjetland EF, Ndhlovu PD, Mduluza T, Deschoolmeester V, Midzi N, Gomo E, et al.
494 The effects of genital *Schistosoma haematobium* on human papillomavirus and the
495 development of neoplasia after 5 years in a Zimbabwean population. A pilot study. *Eur*
496 *J Gynec Oncol* [Internet]. 2010/06/10. 2010;31(2):169–73. Available from:
497 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20527233)
498 [ation&list_uids=20527233](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20527233)
- 499 11. Lalaina N, Irène RZ, Patrick M, Gabriël RP, Soa R. Schistosomiasis with Cervical
500 Cancer: About 2 Cases and Literature Review. *Open J Pathol*. 2021;11(01):1–6.
- 501 12. Kutz JM, Rausche P, Rasamoelina T, Ratefiarisoa S, Razafindrakoto R, Klein P, et al.
502 Female genital schistosomiasis, human papilloma virus infection, and cervical cancer
503 in rural Madagascar: a cross sectional study. *Infect Dis poverty* [Internet].
504 2023;12(1):89. Available from: <https://doi.org/10.1186/s40249-023-01139-3>
- 505 13. Kjetland EF, Ndhlovu PD, Kurewa EN, Midzi N, Gomo E, Mduluza T, et al.
506 Prevention of gynecologic contact bleeding and genital sandy patches by childhood
507 anti-schistosomal treatment. *Am J Trop Med Hyg* [Internet]. 2008/07/09. 2008

- 508 Jul;79(1):79–83. Available from:
509 <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit>
510 [ation&list_uids=18606767](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit&list_uids=18606767)
- 511 14. World Health Organisation. Deworming adolescent girls and women of reproductive
512 age: Policy brief [Internet]. 2021. Available from:
513 <https://www.who.int/publications/i/item/9789240037670>
- 514 15. World Health Organization. Helminth control in school-age children: A guide for
515 managers of control programmes. 2011.
- 516 16. Lothe A, Oyhus AO. Treating Bilharzia among High School Pupils. A study of
517 opportunities and constraints for treating Bilharzia among high school pupils in Ugu
518 district, South Africa. Vol. Masters, Faculty of Economics and Social Sciences.
519 [Development Management]: Agder University College; 2012.
- 520 17. Lothe A, Zulu N, Øyhus AO, Kjetland EF, Taylor M. Treating schistosomiasis among
521 South African high school pupils in an endemic area, a qualitative study. *BMC Infect*
522 *Dis*. 2018;18(1):1–10.
- 523 18. Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S, Gyapong M. A major
524 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps
525 in knowledge and understanding of female genital schistosomiasis within communities
526 and local health workers. Hsieh MH, editor. *PLoS Negl Trop Dis* [Internet]. 2019 Mar
527 21 [cited 2019 Apr 2];13(3):e0007207. Available from:
528 <http://dx.plos.org/10.1371/journal.pntd.0007207>
- 529 19. Sommerfelt I, Ndhlovu P, Taylor M, Naidoo S, Pillay P, Haaland H, et al. Health
530 professionals’ knowledge about female genital schistosomiasis. A qualitative
531 investigation in a schistosomiasis endemic area in South Africa. *SSM - Qual Res Heal*
532 [Internet]. 2023 Jun 1 [cited 2023 Jun 26];3:100292. Available from:
533 <https://linkinghub.elsevier.com/retrieve/pii/S2667321523000768>
- 534 20. Toller A, Scopin AC, Apfel V, Prigenzi KC, Tso FK, Focchi GR, et al. An interesting
535 finding in the uterine cervix: *Schistosoma hematobium* calcified eggs. *Autops Case*
536 *Rep* [Internet]. 2015/10/21. 2015;5(2):41–4. Available from:
537 <http://www.ncbi.nlm.nih.gov/pubmed/26484333>
- 538 21. Mazigo HD, Samson A, Lambert VJ, Kosia AL, Ngoma DD, Murphy R, et al. “We
539 know about schistosomiasis but we know nothing about FGS”: A qualitative
540 assessment of knowledge gaps about female genital schistosomiasis among
541 communities living in *Schistosoma haematobium* endemic districts of Zanzibar and
542 Northwestern Tanzania. Knopp S, editor. *PLoS Negl Trop Dis* [Internet]. 2021 Sep 30
543 [cited 2021 Oct 4];15(9):e0009789. Available from:
544 <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009789>
- 545 22. Engels D, Hotez PJ, Ducker C, Gyapong M, Bustinduy AL, Secor WE, et al.
546 Integration of prevention and control measures for female genital schistosomiasis, HIV
547 and cervical cancer. *Bull World Health Organ*. 2020;98(9):615–24.
- 548 23. Søfteland S, Sebitloane MH, Taylor M, Roald BB, Holmen S,
549 Galappaththi-Arachchige HN, et al. A systematic review of handheld tools in lieu of
550 colposcopy for cervical neoplasia and female genital schistosomiasis. *Int J Gynecol*
551 *Obstet* [Internet]. 2021 Feb 12 [cited 2021 Feb 9];153(2):190–9. Available from:
552 <https://onlinelibrary.wiley.com/doi/10.1002/ijgo.13538>
- 553 24. Norseth HM, Ndhlovu PD, Kleppa E, Randrianasolo BS, Jourdan PM, Roald B, et al.
554 The colposcopic atlas of schistosomiasis in the lower female genital tract based on
555 studies in Malawi, Zimbabwe, Madagascar and South Africa. *PLoS Neglected Trop*
556 *Dis* [Internet]. 2014 Nov;8(11):e3229 (1-17). Available from:
557 <http://europepmc.org/abstract/med/25412334>
- 558 25. Mbabazi PS, Vwalika B, Randrianasolo BS, Roald B, Ledzinski D, Olowookorun F, et
559 al. World Health Organisation Female genital schistosomiasis. A pocket atlas for
560 clinical health-care professionals [Internet]. Vol. 2015, WHO/HTM/NTD/2015.4.

- 561 Geneva: WHO; 2015. 1–49 p. Available from:
562 http://apps.who.int/iris/bitstream/10665/180863/1/9789241509299_eng.pdf
- 563 26. Kjetland EF, Kurewa EN, Ndhlovu PD, Midzi N, Gwanzura L, Mason PR, et al.
564 Female genital schistosomiasis - a differential diagnosis to sexually transmitted
565 disease: Genital itch and vaginal discharge as indicators of genital *S. haematobium*
566 morbidity in a cross-sectional study in endemic rural Zimbabwe. *Trop Med Int Heal*.
567 2008;13(12):1509–17.
- 568 27. Randjelovic A, Frønæs SG, Munsami M, Kvalsvig JD, Zulu SG, Gagai S, et al. A
569 study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa.
570 *South African Fam Pract* [Internet]. 2015 [cited 2019 Jun 3];57(2):57–61. Available
571 from:
572 <https://www.tandfonline.com/action/journalInformation?journalCode=ojfp20><http://dx.doi.org/10.1080/20786190.2014.978121>
- 573 28. Berge ST, Kabatereine NB, Gundersen SG, Taylor M, Kvalsvig JD, Mkhize-
574 Kwitshana Z, et al. Generic praziquantel in South Africa: The necessity for policy
575 change to avail cheap, safe and efficacious schistosomiasis drugs to the poor, rural
576 population. *South Afr J Epidemiol Infect* [Internet]. 2011 [cited 2013 Jan
577 26];26(1):22–5. Available from: <http://sajei.co.za/index.php/SAJEI/article/view/302>
- 578 29. National Department of Health. Schistosomiasis Mass Drug Administration Plan.
579 National Department of Health, South Africa; 2023. 1–31 p.
- 580 30. Galappaththi-Arachchige HN, Holmen S, Koukounari A, Kleppa E, Pillay P,
581 Sebitloane M, et al. Evaluating diagnostic indicators of urogenital *Schistosoma*
582 *haematobium* infection in young women: A cross sectional study in rural South Africa.
583 *PLoS One*. 2018;13(2):1–15.
- 584 31. Republic of South Africa. Children’s Act, 2005. Government Gazette, 28944 South
585 Africa: Government Gazette; 2006 p. 48.
- 586 32. Nguyen VK, Eaton JW. Trends and country-level variation in age at first sex in sub-
587 Saharan Africa among birth cohorts entering adulthood between 1985 and 2020. *BMC*
588 *Public Health* [Internet]. 2022;22(1):1–11. Available from:
589 <https://doi.org/10.1186/s12889-022-13451-y>
- 590 33. Chartsbin. No Title [Internet]. [cited 2023 Jan 18]. Available from:
591 <http://chartsbin.com/view/xxj>
- 592 34. Mkasi L, Rafudeen A. Debating Virginity-testing Cultural Practices in South Africa: A
593 Taylorian Reflection. *J Study Relig* [Internet]. 2016;29(2016):118–33. Available from:
594 <http://www.scielo.org.za/pdf/jsr/v29n2/07.pdf>
- 595 35. Durojaye E. The human rights implications of virginity testing in South Africa. *Int J*
596 *Discrim Law*. 2016;16(4):228–46.
- 597 36. Department of Basic Education. School Masterlist Data [Internet]. March 2017.
598 Quarter 4 of 2016. Pretoria; 2017. Available from:
599 <https://www.education.gov.za/Programmes/EMIS/EMISDownloads.aspx>
- 600 37. Livingston M, Pillay P, Zulu SG, Sandvik L, Kvalsvig JD, Gagai S, et al. Mapping
601 *Schistosoma haematobium* for novel interventions against Female Genital
602 Schistosomiasis and associated HIV risk in KwaZulu-Natal, South Africa. *Am J Trop*
603 *Med Hyg*. 2021;104(6):2055–2064.
- 604 38. National Department of Health. Elimination of Schistosomiasis and Soil Transmitted
605 Helminths as Public Health Problems in South Africa. 2010. p. 1–48.
- 606 39. Kleppa E, Ramsuran V, Zulu S, Karlsen GH, Bere A, Passmore J-A, et al. Effect of
607 Female Genital Schistosomiasis and anti- schistosomal treatment on monocytes, CD4+
608 T-cells and CCR5 expression in the female genital tract. *PLoS One* [Internet].
609 2014;9(6):e98593 (1-9). Available from: <http://europepmc.org/abstract/med/24896815>
- 610 40. Kleppa E, Klinge KF, Galaphaththi-Arachchige HN, Holmen SD, Lillebø K, Onsrud
611 M, et al. *Schistosoma haematobium* Infection and CD4+ T-cell levels: A cross-
612 sectional study of young South African women. *PLoS One*. 2015;10(3):1–9.
- 613

- 614 41. Kleppa E, Holmen SD, Lillebø K, Kjetland EF, Gundersen SG, Taylor M, et al.
615 Cervical ectopy: associations with sexually transmitted infections and HIV. A cross-
616 sectional study of high school students in rural South Africa. *Sex Transm Infect.*
617 2015;91:124–9.
- 618 42. Nemungadi TG, Furumele TE, Gugerty MK, Djirmay AG, Naidoo S, Kjetland EF.
619 Establishing and Integrating a Female Genital Schistosomiasis Control Programme
620 into the Existing Health Care System. *Trop Med Infect Dis* 2022, Vol 7, Page 382
621 [Internet]. 2022 Nov 16 [cited 2022 Nov 21];7(11):382. Available from:
622 <https://www.mdpi.com/2414-6366/7/11/382/htm>
- 623 43. South African National Department of Health. Regular treatment of school-going
624 children for soil-transmitted helminth infections and Bilharzia: Policy and
625 implementation guidelines. Pretoria, South Africa: The South African National
626 Department of Health; 2008 p. 38.
- 627 44. van Bogaert L. Case of invasive adenocarcinoma of the cervix in a human
628 immunodeficiency virus and schistosome co-infected patient. *South African J*
629 *Gynaecol Oncol.* 2014;6(1):5–6.
- 630 45. Kjetland EF, Mduluzi T, Ndhlovu PD, Gomo E, Gwanzura L, Midzi N, et al. Genital
631 schistosomiasis in women: a clinical 12-month in vivo study following treatment with
632 praziquantel. *Trans R Soc Trop Med Hyg* [Internet]. 2006;100(8):740–52. Available
633 from: <http://www.ncbi.nlm.nih.gov/pubmed/16406034>
- 634 46. Downs JA, Kabangila R, Verweij JJ, Jaka H, Peck RN, Kalluvya SE, et al. Detectable
635 urogenital schistosome DNA and cervical abnormalities 6 months after single-dose
636 praziquantel in women with *Schistosoma haematobium* infection. *Trop Med Int Heal*
637 [Internet]. 2013/08/14. 2013;18(9):1090–6. Available from:
638 <http://www.ncbi.nlm.nih.gov/pubmed/23937701>
- 639 47. van Bogaert LJ. Schistosomiasis - an endemic but neglected tropical disease in
640 Limpopo. Vol. 100, *South African Medical Journal.* 2010. p. 788–9.
- 641 48. Feldmeier H, Poggensee G, Krantz I. A synoptic inventory of needs for research on
642 women and tropical parasitic diseases. II. Gender-related biases in the diagnosis and
643 morbidity assessment of schistosomiasis in women. *Acta Trop* [Internet]. 1993/11/01.
644 1993 Nov;55(3):139–69. Available from:
645 <http://www.ncbi.nlm.nih.gov/pubmed/7903838>
- 646 49. Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S, Gyapong M. A major
647 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps
648 in knowledge and understanding of female genital schistosomiasis within communities
649 and local health workers. Hsieh MH, editor. *PLoS Negl Trop Dis.* 2018
650 Mar;13(3):e0007207.
- 651 50. Bland KG, Gelfand M. The effects of schistosomiasis on the cervix uteri in the African
652 female. *J Obstet Gynaecol Br Commonw* [Internet]. 1970/11/01. 1970;77(11):1127–
653 31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/5493619>
- 654 51. Poggensee G, Kiwelu I, Saria M, Richter J, Krantz I, Feldmeier H. Schistosomiasis of
655 the lower reproductive tract without egg excretion in urine. *Am J Trop Med Hyg*
656 [Internet]. 1998;59(5):782–3. Available from: [http://www.ncbi.nlm.nih.gov/htbin-](http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597)
657 [post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597](http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597)
- 658
659